Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LFWD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLifeward promotes Keith D. Rose, M.D. to Chief Medical Officer
Filed May 19, 2026 · Period ending May 18, 2026 · ~1 min read
Key Changes
-
medium
Dr. Keith D. Rose appointed Chief Medical Officer effective May 1, 2026, promoted from VP of Medical Affairs after three years with the company. The CMO role is critical for clinical strategy and regulatory interactions at medical device firms.
Item 5.02 view on EDGAR → -
low
Dr. Rose brings experience from Novocure, Biocodex, Ipsen, and Jazz Pharmaceuticals, with medical training in Physical Medicine & Rehabilitation—directly relevant to Lifeward's neuroscience-focused medical devices.
8-K: Executive Background view on EDGAR →
Summary
Lifeward filled its Chief Medical Officer position by promoting Dr. Keith D. Rose, who has been with the company since March 2023 in medical affairs roles focused on neurosciences. This internal promotion suggests continuity in clinical strategy and familiarity with the company's product pipeline and regulatory environment.
For retail investors, the CMO appointment matters because this role typically drives clinical trial design, physician engagement, and regulatory submissions—all critical to a medical device company's ability to expand indications and market access. Dr. Rose's background in physical medicine and rehabilitation aligns well with Lifeward's focus area. Watch for any upcoming clinical trial announcements or regulatory filings that would reflect the new CMO's strategic priorities, particularly around expanding the use cases for Lifeward's neuroscience devices.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 18, 2026, Lifeward Ltd. (the “Company”) announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer of the Company, effective as of May 1, 2026.
The company appointed Dr. Keith D. Rose as Chief Medical Officer effective May 1, 2026. Dr. Rose has been with the company since March 2023 in various medical affairs roles, most recently as Vice President, Medical Affairs, Medical Director – Neurosciences. This represents a promotion from within and fills a key executive medical leadership position.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Before joining the Company, Dr. Rose served as the Medical Director, Medical Affairs at Biocodex, Inc. from November 2021 to June 2023 and Lead Clinical Research Scientist/Regional Manager in Oncology at Novocure, Inc. (NASDAQ: NVCR) from June 2020 to November 2021. Prior to those roles, Dr. Rose held various senior medical affairs and clinical leadership positions at Biocodex, Ipsen, Biosciences, Inc., Jazz Pharmaceuticals plc and Indivior PLC.
Dr. Rose brings extensive medical affairs and clinical leadership experience from multiple pharmaceutical and medical device companies including Novocure, Biocodex, Ipsen, Jazz Pharmaceuticals, and Indivior. He holds an M.D. from George Washington University and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine, providing relevant credentials for a medical device company focused on neurosciences.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify